NCT06154278View on ClinicalTrials.gov

Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

July 1, 2027

Conditions
Chronic Hepatitis B
Interventions
DRUG

Imdusiran (AB-729)

60mg subcutaneously, every 8 weeks, for a total of 4 doses

Trial Locations (1)

21201

RECRUITING

Institute of Human Virology, University of Maryland School of Medicine, Baltimore

Sponsors
All Listed Sponsors
collaborator

Arbutus Biopharma Corporation

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT06154278 - Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B | Biotech Hunter | Biotech Hunter